Skip to main content
FDA OKs Roche's companion Dx assay for Novartis' lung cancer drug
6/2/2017

Roche Holding has obtained approval from the FDA for its Ventana ALK (D5F3) CDx Assay, which is intended for determining which patients may respond to Novartis' non-small cell lung cancer drug Zykadia. The immunohistochemistry test, which can be used on BenchMark IHC/ISH instruments, is also indicated as a companion diagnostic for Pfizer's ALK inhibitor Xalkori.

Full Story: